Preliminary studies in animal models of HCM suggested possible benefits of angiotensin II receptor blockers, 3-hydroxy-3-methyglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), mineralocorticoid receptor blockers, and anti-oxidant N-acetylcysteine